|
|
Characterizing the Impact of Auditory Experience on Language, Cognitive, and Neural Development in Children |
| 1P20GM144641-01 |
|
NIGMS |
2022 |
|
|
Targeting AbcA1 and Ldlr production for the Discoveryof Alzheimers disease Drugs |
| 1R16GM145547-01 |
|
NIGMS |
2022 |
|
|
Effect of dietary restriction and exercise on behavioral outcomes and brain pathology in a transgenic model of Alzheimers disease |
| 2P20GM113109-06 |
|
NIGMS |
2022 |
|
|
Determining the role of a novel brainstem pathway in normal circadian function and in Alzheimers disease related dysfunction and sundowning-associated behavior |
| 2P20GM121310-06 |
|
NIGMS |
2022 |
|
|
Strategic Reprogramming of the Ergot Alkaloid Pathway |
| 2R15GM114774-03 |
|
NIGMS |
2022 |
|
|
Emerging imaging technologies for automated analyses of calcineurin-dependent brain function |
| 3R01GM136906-03S1 |
|
NIGMS |
2022 |
|
|
Quantitative 3D imaging of in situ nanoparticle movement and cellular behavior during neuroinflammation |
| 3R35GM124677-06S1 |
|
NIGMS |
2022 |
|
|
Regulation of microRNA-218 by TRIM9 in Alzheimers Disease and relhttps://apps.era.nih.gov/gmii/manage/view.era?applId=10497234#ated dementia |
| 3R35GM128753-05S1 |
|
NIGMS |
2022 |
|
|
Investigating structural heterogeneities in amyloid aggregates with multiscale infrared spectroscopic imaging |
| 3R35GM138162-03S1 |
|
NIGMS |
2022 |
|
|
Acquisition of a MICRON IV ocular imaging system |
| 3U54GM104941-10S1 |
|
NIGMS |
2022 |
